Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
Open Access
- 3 May 2022
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (9) , e024656
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic CardiomyopathyJAMA Cardiology, 2016
- A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in miceScience, 2016
- Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management StrategiesJACC, 2015
- Short and Medium Term Outcomes of Surgery for Patients With Hypertrophic Obstructive CardiomyopathyThe Annals of Thoracic Surgery, 2015
- Long-Term Survival in Patients With Resting Obstructive Hypertrophic CardiomyopathyJACC, 2011
- Current Effectiveness and Risks of Isolated Septal Myectomy for Hypertrophic Obstructive CardiomyopathyThe Annals of Thoracic Surgery, 2008
- Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic CardiomyopathyJACC, 2005
- Assessment of Permanent Dual-Chamber Pacing as a Treatment for Drug-Refractory Symptomatic Patients With Obstructive Hypertrophic CardiomyopathyCirculation, 1999
- Pacing in hypertrophic obstructive cardiomyopathy: A randomized crossover studyEuropean Heart Journal, 1997
- A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathyJACC, 1993